Hospital-acquired pneumonia in patients receiving immunosuppressive therapy

Basit Öğe Kaydı
dc.authorwosid, Osman/AGR-7980-2022
dc.authorwosid, osman/HRD-6024-2023
dc.contributor.authorEdis, Ebru Cakir
dc.contributor.authorHatipoglu, Osman Nuri
dc.contributor.authorYilmam, Ilker
dc.contributor.authorEker, Alper
dc.contributor.authorTansel, Ozlem
dc.contributor.authorSut, Necdet
dc.contributor.authorTekgunduz, Emre
dc.date.accessioned2024-06-12T11:03:42Z
dc.date.available2024-06-12T11:03:42Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: The aims of this study were to determine the clinical success rates, effect of neutropenia on treatment success rates, risk factors related to mortality, and survival in patients who developed hospital-acquired pneumonia (HAP) while receiving immunosuppressive therapy. Materials and Methods: Forty-three adult patients receiving immunosuppressive therapy who developed HAP were included in this prospective study. Transplantation patients and human immunodeficiency virus (HIV)-positive patients were not included. Antibiotic treatment was managed by a multidisciplinary team. The Kaplan Meier method was used for the survival analysis and Cox regression was used for the identification of mortality-related independent risk factors. The relationship between neutropenia and the clinical success rate was determined using the chi-square test. Results: Although anti-pseudomonal antibiotics were started empirically in 40 of the 43 patients (93%) at the beginning of the treatment, the most frequently isolated pathogens were Acinetobacter spp. and Escherichia coli. The success rate at the end of the treatment was 65.1%. The survival rates for the 3(rd), 14(th), 42(nd), and 365(th) days were 97%, 86%, 58%, and 19%, respectively. Elevated levels of urea [Hazard Ratio=1.01 (95% Cl: 1.00-1.02)] and blood glucose [HR=1.01 (95% Cl: 1.00-1.02)] were found to be independent risk factors affecting survival. The treatment success rate was higher in patients without neutropenia (n=23) than in those with neutropenia (n=20) (p=0.05). Conclusion: The treatment success rate was low in patients who developed HAP while receiving immunosuppressive therapy. (Turk J Hematol 2010; 27: 20-4)en_US
dc.identifier.endpage24en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1en_US
dc.identifier.pmid27265793en_US
dc.identifier.scopus2-s2.0-77649281030en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage20en_US
dc.identifier.trdizinid99333en_US
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/99333
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21759
dc.identifier.volume27en_US
dc.identifier.wosWOS:000275387000004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunocompromised Patientsen_US
dc.subjectHospital-Acquired Pneumoniaen_US
dc.subjectSurvivalen_US
dc.titleHospital-acquired pneumonia in patients receiving immunosuppressive therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu